InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,815.03
(
0.61%
)
US TECH 100
19,708.00
(
0.02%
)
Dow Jones
42,863.86
(
0.97%
)
Brent Oil
78.70
(
-0.46%
)
Bitcoin
62,477.54
(
3.66%
)
Post# of 253343
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120560
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 62851

Tuesday, 06/23/2009 1:17:41 AM

Tuesday, June 23, 2009 1:17:41 AM

Post# of 253343
AMGN – Prolia (a/k/a/ Denosumab) FDA panel
meets on Aug 13. There will be a lot to talk about.

http://finance.yahoo.com/news/Amgen-to-Participate-in-prnews-2914916306.html

Amgen's BLA submission contains data from six Phase 3 trials involving more than 11,000 patients and approximately 13,000 patient years of exposure to denosumab…

…the proposed indications [are] treatment and prevention of osteoporosis in postmenopausal women, and treatment and prevention of bone loss in patients undergoing hormone ablation for prostate or breast cancer.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up